Heparin-induced thrombocytopenia

被引：320

作者：

Arepally, Gowthami M. ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Div Hematol, Durham, NC USA

来源：

BLOOD | 2017年 / 129卷 / 21期

基金：

美国国家卫生研究院;

关键词：

MOLECULAR-WEIGHT HEPARIN; FACTOR 4/HEPARIN ANTIBODIES; PLATELET-AGGREGATION TEST; TISSUE FACTOR EXPRESSION; UNFRACTIONATED HEPARIN; CARDIOPULMONARY BYPASS; THROMBOEMBOLIC COMPLICATIONS; WARFARIN THROMBOPROPHYLAXIS; ANTITHROMBOTIC PROPHYLAXIS; CONFORMATIONAL-CHANGES;

D O I：

10.1182/blood-2016-11-709873

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic antibodies to PF4/heparin bind and activate cellular Fc gamma RIIA on platelets and monocytes to propagate ahypercoagulable state culminating in life-threatening thrombosis. It is now recognized that anti-PF4/and laboratory findings have also been recently harnessed for disease prevention. This review will summarize our current understanding of HIT by reviewing pathogenesis, essential clinical and laboratory features, and management.

引用

页码：2864 / 2872

页数：9

共 131 条

[1] Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - A European Perspective [J].